CAS: 221615-75-4; 1-(6-Methylpyridin-3-yl)-2-(4-(Methylsulfonyl)Phenyl)Ethanone

相似化合物

307531-95-9 1027162-35-1 221615-72-1

上下游产品

CAS号221615-72-1 1-(6-甲基-3-吡啶)-2... | CAS号36357-38-7 5-乙酰基-2-甲基嘧啶 | CAS号3466-32-8 4-溴苯甲砜 | CAS号5470-70-2 6-甲基烟酸甲酯 | CAS号90536-66-6 4-甲磺酰基苯乙酸 | CAS号98-57-7 4-氯苯基甲基砜 | CAS号111770-91-3 6-甲基-3-吡啶三氟甲烷磺酸 | CAS号1121-78-4 3-羟基-6-甲基吡啶 | CAS号325855-74-1 5-氯-6'-甲基-3-(4-... | CAS号202409-33-4 依托考昔

3-羟基-6-甲基吡啶置于哌啶,吡啶,Bis(Acetylacetonato)Palladium(II),Potassium Phosphate,硫酸,Palladium Diacetate,三对苯甲基膦,4,5-双二苯基膦-9,9-二甲基氧杂蒽,Sodium Hydroxide体系中,用 N-甲基吡咯烷酮,二氯甲烷,二甲基亚砜,甲苯 用作溶剂,化学反应 38.5H,反应生成2-(4-甲磺酰基苯基)-1-(6-甲基吡啶-3-基)-乙酮
参考文献:选择性cox-2抑制剂etoricoxib †的关键中间体的便捷合成
标题:选择性cox-2抑制剂etoricoxib †的关键中间体的便捷合成
摘要:酮1(制备的关键中间体)的原始合成策略.依托昔布一种重要的非甾体类抗炎药已经开发出来.便宜的5-羟基-2-甲基吡啶在四个实际的合成步骤中,将其转化为相应的乙酰基衍生物.以下钯催化的α-芳基化乙酰基吡啶 与4-溴或 4-氯苯基甲基砜为了得到显着收率的酮1,有效率地对其进行了优化.
Doi:10.1039/c3Ra42619J

专利信息

专利号:US-5760249-A
优先权日:1995-08-29
标题 :Synthesis of hydroxysulfone and related compounds
发明人：MATHRE DAVID J; SOHAR PAUL; MOODY DAVID; BLACKER ANDREW J
权利人:MERCK & CO INC; ZENECA LTD
摘要:This invention is concerned with an improved process for the synthesis of hydroxysulfone, which is a key intermediate in the synthesis of carbonic anhydrase inhibitors, especially dorzolamide. Carbonic anhydrase inhibitors are known to be effective in treating elevated intraocular pressure or glaucoma.

专利号:EP-0853625-B1
优先权日:1995-08-29
标 题:Synthesis of hydroxysulfone and related compounds
发明人：MATHRE DAVID J; SOHAR PAUL; MOODY DAVID; BLACKER ANDREW J
权利人:MERCK & CO INC; SYNGENTA LTD
摘要:This invention is concerned with an improved process for the synthesis of hydroxysulfone, which is a key intermediate in the synthesis of carbonic anhydrase inhibitors, especially dorzolamide. Carbonic anhydrase inhibitors are known to be effective in treating elevated intraocular pressure or glaucoma.

专利号:US-2005165238-A1
优先权日:2001-12-19
标题 :Oxidation process for the preparation of intermediates useful in the synthesis of diarylpyridines
发明人：CANNATA VINCENZO; SORIATO GIORGIO; VERZINI MASSIMO
摘要:An oxidation process for the preparation of intermediates useful in the synthesis of diarylpiridines is described. The oxidation of the thioether of formula III to give the sulfone of formula II is is carried out with a mixture of peracetic acid and hydrogen peroxide as oxidant, in the presence of methanesulphonic acid and in the absence of a catalylst.

专利号:US-9024030-B2
优先权日:2012-01-13
标题 :Process for the synthesis of etoricoxib
发明人：MAO ZHENMIN; LAN TIAN; LIU LANFANG; YAN LONG; BECKER STEFAN
权利人:TIEFENBACHER ALFRED E GMBH & CO KG; SHANGHAI GOLDEN PHARMATECH CO LTD; SHANGHAI GOLDEN PHARMATECH CO LTD
摘要:The present invention relates to a process for the synthesis of the anti-inflammatory agent 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridine, referred to as compound of formula (1) or etoricoxib, which is a pharmaceutically active ingredient inhibiting cyclooxygenase-2. In particular, the application concerns a novel process of making the compound of formula (1) by oxidizing a compound of formula (4).

专利号:US-8664402-B2
优先权日:2011-03-09
标题:Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib
发明人：CASTELLIN ANDREA; STABILE PAOLO; FONTANA FRANCESCO; DE LUCCHI OTTORINO; CAPORALE ANDREA; TARTAGGIA STEFANO
权利人:CASTELLIN ANDREA; STABILE PAOLO; FONTANA FRANCESCO; DE LUCCHI OTTORINO; CAPORALE ANDREA; TARTAGGIA STEFANO; ITALIANA SINT SPA
摘要:A process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methyl sulfonyl)phenyl]ethanone, an intermediate of the synthesis of Etoricoxib. The synthesis of the intermediates useful for such preparation is also described.

专利号:US-5157129-A
优先权日:1990-04-18
标题:Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
发明人：BLACKLOCK THOMAS J; JONES TODD K; GRABOWSKI EDWARD J J; MATHRE DAVID J; MOHAN JULIE J; SOHAR PAUL; ROBERTS F EDWARD; XAVIER LYNDON C
权利人:MERCK & CO INC
摘要:5,6-Dihydro-4-(R-amino)-4H-thieno[2,3-b]-thiopyran-2-sulfonamide-7,7-dioxide is a potent carbonic anhydrase inhibitor useful in the treatment of ocular hypertension and glaucoma. The S-(+)-enantiomer of that compound, the more active enantiomer, is prepared by a process involving an intermediate step of an enantioselective reduction of a carbonyl group employing an oxazaborolidine chiral catalyst.